Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on November 18, 2025, and filed on November 19, 2025. The filing details a share repurchase executed through BNP Paribas SA as part of GSK's existing buyback programme, which was announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital structure changes via share repurchases rather than operational financial performance (revenue, profit, or cash flow).
- Shares Purchased: 185,000 ordinary shares.
- Price Range: Lowest price paid was 1,771.00 GBp; highest price paid was 1,803.00 GBp.
- Average Price: Volume-weighted average price (VWAP) was 1,780.45 GBp.
- Treasury Holdings: Following this purchase, GSK holds 234,819,844 ordinary shares in treasury.
- Shares in Issue: 4,080,611,266 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.75% of total voting rights.
Material Changes vs. Prior Period
This filing represents a continuation of the buyback programme initiated on September 30, 2025. Since the programme's inception, GSK has purchased a total of 9,355,000 ordinary shares. The filing does not provide comparative operational data (e.g., revenue or earnings) against prior periods.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's 2024 Annual Report on Form 20-F and Q3 2025 Results. The repurchase was effected pursuant to a non-discretionary agreement with the broker.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since September 30, 2025 (stated as 9,355,000).
- Confirm the updated treasury share count of 234,819,844 and the resulting 5.75% voting rights attribution.
- Review the specific trading venues (BATE, CHIX, XLON) and transaction timestamps to ensure compliance with market rules.
- Check the company's Form 20-F and Q3 2025 results for broader context on liquidity and debt capacity supporting the buyback.